Current therapeutic strategies in cardiac amyloidosis

Current Treatment Options in Cardiovascular Medicine

Volumn 7, Issue 6, 2005, Pages 443-448

  Parikh, Shailja ^b   de Lemos, James A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; AMYLOID; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10; BRAIN NATRIURETIC PEPTIDE; COLCHICINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MELPHALAN; NIFEDIPINE; PREDNISONE; VASODILATOR AGENT; WARFARIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONSTRICTIVE PERICARDITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE RESPONSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GRAFT FAILURE; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PROTEIN ANALYSIS; RECTUM BIOPSY; RECTUM MUCOSA; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 28644432214     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-005-0029-8     Document Type: Review

References (24)

1. Kyle R: Amyloidosis. Circulation 1995, 91:1269-1270.
2. Grogan M, Gertz MA, Kyle R, et al.: Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2000, 85:664-665.
3. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-596.
4. Jacobson D, Pastore R, Yaghoubian R, et al.: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997, 336:466-473.
5. Swanton R, Brooksby I, Davies M, et al.: Systolic and diastolic ventricular function in cardiac amyloidosis: studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol 1977, 39:658-664.
6. Liao R, Jain M, Teller P, et al.: Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001, 104:1594-1597.
7. Chew C, Mokhtar G, Raphael M: The functional defect in amyloid heart disease: the "stiff heart" syndrome. Am J Cardiol 1975, 36:438-444.
8. Carroll J, Gaasch W, McAdam P: Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982, 49:9-13.
9. Palladini G, Campana C, Klersy C, et al.: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker for myocardial dysfunction in AL amyloidosis. Circulation 2003, 107:2440-2445.
10. Rahman J, Helou E, Gelzer-Bell R, et al.: Noninvasive diagnosis of biopsy proven cardiac amyloidosis. J Am Coll Cardiol 2004, 43:410-415.
11. Fatorri R, Rocchi G, Cellati F, et al.: Contribution of magnetic resonance imaging in identification of amyloid cardiomyopathy. Am Heart J 1998, 136:824-830.
12. Kwong R, Falk R: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005, 111:122-124.
13. Rubinow A, Skinner M, Cohen A: Digoxin sensitivity in amyloid cardiomyopathy, Circulation 1981, 63:1285-1288.
14. Gertz M, Skinner M, Connors L: Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985, 55:1646.
15. Choufani E, Sanchorawala V, Ernst T, et al.: Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001, 97:1885-1887.
16. Kyle R, Gertz M, Greipp P, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202-1207.
17. Gertz M, Lacy M, Just J, et al.: Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999, 17:262-267.
18. Skinner M, Sanchorawala V, Seldin D, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
19. Comenzo R, Vosburgh E, Falk R: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662-3670.
20. Gianni L, Bellotti V, Gianni M, et al.: New drug therapy of amyloidosis: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995, 86:855-861.
21. Merlini G, Anesi E, Garini P, et al.: Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: an update. Blood 1999, 93:1112-1113.
22. Dubrey S, Burke M, Khaghani A, et al.: Long-term results of heart transplantation in patients with amyloid heart disease. Heart 2001, 85:202-207.
23. Cohen H, Lessin L, Kyle R, et al.: Resolution of primary amyloidosis during chemotherapy: studies in patients with nephrotic syndrome. Ann Intern Med 1975, 82:466-473.
24. Merlini G, Ascari E, Amboldi N, et al.: Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995, 92:2959-2963.